Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form (ICF), and where appropriate, signed assent form.~* Participants entering the Part A Treatment Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104 and elect to enroll in Part A treatment cohort.~* Participants entering the Part B Treatment Cohort: Completed 56 days of study drug treatment in Cohort 4 of Study 102 and elect to enroll in Part B treatment cohort.~* Participants entering the Part A Observational Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104, but do not elect to enroll in the Part A Treatment Cohort or do not qualify to enroll in Part A treatment cohort.~* Willing to remain on a stable CF medication regimen through the end of study (Part A and Part B Treatment Cohorts only).~Exclusion Criteria:~* Any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant (e.g., cirrhosis with portal hypertension).~* Pregnant and nursing females. Females of childbearing potential must have a negative pregnancy test at the Day 1 Visit.~* History of drug intolerance in the prior study that would pose an additional risk to the participant in the opinion of investigator or Vertex.~* History of poor compliance with study drug and/or procedures in the previous study as deemed by the investigator.~* Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor, or studies requiring blood collections with or without administration of study drug)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
- Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
- Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
- Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
- Arm 5 Part A: Observational Cohort (Type: NO_INTERVENTION): Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
- Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
- Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.

Based on this trial design, predict the completion outcome and termination type (if applicable).